Principal Scientist
EVOLVEIMMUNE THERAPEUTICS INC
Summary
In this role you will execute translational immunology research to support IND enabling activities and phase I clinical studies in oncology. Experience in immune-assay development and expertise in human immunology and T cell immunobiology are required. The role involves experimental design (CRO and internal) and execution (bench work) as well as interpretation and presentation of results. This is an exciting opportunity for a highly collaborative and creative scientist who is eager to position novel immunotherapies in the cancer immunology treatment landscape. Close collaboration and matrix working with members of the Immunobiology, Biotherapeutics and Translational Sciences teams are expected. Evidence for a track record of scientific and/or project achievements is preferred.
Job description
What You’ll Work on
In this role you will execute translational immunology research to support IND enabling activities and phase I clinical studies in oncology. Experience in immune-assay development and expertise in human immunology and T cell immunobiology are required. The role involves experimental design (CRO and internal) and execution (bench work) as well as interpretation and presentation of results. This is an exciting opportunity for a highly collaborative and creative scientist who is eager to position novel immunotherapies in the cancer immunology treatment landscape. Close collaboration and matrix working with members of the Immunobiology, Biotherapeutics and Translational Sciences teams are expected. Evidence for a track record of scientific and/or project achievements is preferred.
- Design and conduct in vitro studies with an emphasis on immunological testing of human and animal samples using state-of-the-art techniques including immune cell functional assays, multi-parameter FACS including BD and Cytek instruments, cell separation, multiplex assays, cell toxicity, proliferation
- Perform immune-monitoring related experiments of mouse and clinical samples (tumor, whole blood, PBMC, sera, etc.)
- Provide scientific input to optimize project progression
- Maintain records of experiments in electronic notebooks, analyze data and prepare presentations
- Deliver clear, concise presentations at portfolio and project meetings to enable organizational alignment
- Support the authoring of essential internal and regulatory documents
- Partner with Immunobiology, Biotherapeutics and Translational Science teams to ensure proactive sharing of scientific know-how across the organization
- Ensure compliance with all health and safety protocols
What You Bring
- PhD in immunology or a related fields with 5+ years of postdoctoral and/or industry experience
- Patient focused - dedication to enabling translation of preclinical research into impactful human therapies
- Proven track record in cellular immunology in translational setting demonstrating technical expertise in immune assays and primary cell cultures
- Experience in the field of immune-oncology and large data analytics is a plus
- Capable of clarifying problems and working in collaboration with team members to identify solutions
- Strong verbal and written communication skills
Requirements
- PhD in immunology or a related field
- 5+ years of postdoctoral and/or industry experience
- Experience in immune-assay development
- Expertise in human immunology and T cell immunobiology
- Proven track record in cellular immunology in translational setting
- Technical expertise in immune assays and primary cell cultures
- Strong verbal and written communication skills
Benefits
- Competitive salary
- Equity
- Paid time off
Company overview
EvolveImmune Therapeutics Inc. is an innovative biotechnology company headquartered in Branford, Connecticut, focused on developing next-generation cancer immunotherapies. Founded in 2020, the company specializes in creating first-in-category, multifunctional biotherapeutics designed to overcome cancer-driven immunodeficiency in both solid tumors and hematological cancers. EvolveImmune's proprietary EVOLVE platform pioneers unique trispecific T cell engagers with integrated CD2 costimulation, addressing critical challenges of cancer cell resistance to current immunotherapies. The company's lead internal drug candidate, EVOLVE104, is scheduled to enter clinical trials in 2025. With approximately 57 employees and backed by top-tier life science investors including Pfizer Ventures, Solasta Ventures, and Takeda Ventures, EvolveImmune is advancing a pipeline of novel immunotherapies that aim to provide more effective and durable anti-tumor responses while reducing T cell exhaustion and cytokine release syndrome risks.